CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment
We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.
Neural Network classification of longitudinal cognitive data for prediction of individual-level chan
For the first time, Neural Network classifiers have been applied to changes in CANTAB PAL performance between baseline and 10 months to accurately predict the development of MCI at 20 months. Dr Elizabeth Baker, Statistical Scientist at Cambridge Cognition, presented the novel findings at AAIC 2018.
CANTAB Mobile: experience of use of a digital memory assessment tool in UK primary care
Cambridge Cognition presented new data at AAIC 2018 that demonstrates a demand from patients for the objective assessment of memory function, and describes how CANTAB testing can triage these memory complaints in clinic.
7 tests for assessing cognition in early Alzheimer’s disease
With rising life-expectancy, the number of cases of dementia and related disorders is increasing. In attempts to tackle the pandemic, treatment trials are moving earlier in the disease process. CANTAB offers a battery of tests specially targeted at assessing cognition in early Alzheimer’s disease (AD), and the associated effects on cognition with drug action.
A solution for improving recruitment into early Alzheimer’s disease clinical trials
Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials.
The challenge of detecting early Alzheimer’s disease for clinical trials
In this post, Director of Clinical Affairs, Dr Kenton Zavitz, looks at the challenge of recruiting the correct patients into Alzheimer's disease trials.